Filing Details
Evommune, Inc. (NYSE:EVMN) filed a Form 8-K with the Securities and Exchange Commission on June 29, 2026, disclosing a material event.
8k filedNYSE:EVMN
Evommune, Inc. (EVMN) Reports Material Event to SEC
Filing Details Evommune, Inc. (NYSE:EVMN) filed a Form 8-K with the Securities and Exchange Commission on June 29, 2026, disclosing a material event. Market Context Evommune,…
Market Context
Evommune, Inc.'s stock currently trades at $15.05 with a market capitalization of $261.7M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Evommune, Inc.'s stock.
All SEC filings for Evommune, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View EVMN Stock Page
Frequently Asked Questions
Where can I read EVMN's SEC filings?
Browse all filings on our EVMN SEC filings page.
What types of SEC filings does Evommune, Inc. file?
Public companies like Evommune, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.